WO1987003495A1 - Catheter antimicrobien et procede - Google Patents

Catheter antimicrobien et procede Download PDF

Info

Publication number
WO1987003495A1
WO1987003495A1 PCT/US1986/002668 US8602668W WO8703495A1 WO 1987003495 A1 WO1987003495 A1 WO 1987003495A1 US 8602668 W US8602668 W US 8602668W WO 8703495 A1 WO8703495 A1 WO 8703495A1
Authority
WO
WIPO (PCT)
Prior art keywords
antimicrobial
agent
swelling agent
solution
swelling
Prior art date
Application number
PCT/US1986/002668
Other languages
English (en)
Inventor
Nancy Jane Grove
Original Assignee
Denver Surgical Developments, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denver Surgical Developments, Inc. filed Critical Denver Surgical Developments, Inc.
Publication of WO1987003495A1 publication Critical patent/WO1987003495A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics

Definitions

  • Implanted medical devices which involve catheters, valves, molded parts, etc., and which must reside totally or partially within the human body for relatively long periods of time have historically been plagued with the problem of sepsis.
  • this group of devices include hydrocepha lus shunts, parenteral feeding catheters and foley catheters.
  • extensive colonization of bacteria on the surfaces of the catheter or other part of the device can produce serious patient problems including infection and even the need to replace the implanted devices.
  • a considerable amount of attention and study has been directed to attempting to moderate or eliminate sepsis resulting from such colonization by the use of antimicrobial agents, such as antibiotics, bound to the surface of the materials employed in such devices. In such attempts the objective has been to produce a sufficient bacteriostatic or bacteriocidal action to prevent colonization, and therefore avoid sepsis.
  • BAYSTON, R., and MILNER, R.D.G. "Antimicrobial Activity of Silicone Rubber Used in Hydrocephalus Shunts, after Impregnation with Antimicrobial Substances” J Clin Pathol 1981, 134:1057-1062.
  • BAYSTON, R. "Effect of Antibiotic Impregnation on the Function of Slit Valves Used to Control Hydrocephalus” Z . Kinderchir. Band 31, Heft 4, December 1980.
  • BAYSTON, R. et al "A Model of Catheter Colonization In Vitro and its Relationship to Clinical Catheter Infections", Journal of Infection, 1984, 9 , 271-276.
  • TROOSKIN STANLEY A., M.D., F.A.C.S.: DONETZ, ANTHONY P. B.S.; HARVEY, RICHARD A. Ph.D.: and GRECO, RALPH S. M.D., F.A.C.S., New Brunswick, New Jersey. "Prevention of catheter sepsis by antibiotic bonding", Surgery, 1984. pp 547-551.
  • HARVEY R.A.: GRECO, R.S.: The noncovalent bonding of antibiotics to a polytetrafluoroethylene-benzalkonium graft. Ann Surg 194:642-7, 1981.
  • a treated device can be successfully sterilized by known methods without deleter iously affecting the antimicrobial agent or its bond to the surface of the material of which the device is made. That is, subsequent sterilization tends to shorten the time of antimicrobial activity. It is therefore an objective of the present invention to provide a method by which antimicrobial or antibacterial agents can be incorporated into a wide variety of commonly used materials, so as to provide a relatively longer term protection against bacterial colonization on the surface of that material and a d i mini t ion of the problem of sepsis in implanted and long in-dwelling medical devices.
  • the present invention utilizes swelling agents which are capable of increasing the micro-porosity of selected plastics or naturally occurring materials, and which are compatible with selected antimicrobial or antibacterial agents, preferably dissolving such agents without chemically altering them under conditions and in a manner to permit the infusion of the antibacterial agents selected into the swelled material uniformly and in sufficient amounts to provide for prolonged antimicrobial activity during shelf life and when the infused material is subsequently used in the body.
  • Fig. 1 is a schematic illustration of the perfusion apparatus described herein.
  • Fig. 2 is an illustration of the perfusion chamber of Fig. 1.
  • Fig. 3 is an illustration of the procedure for obtaining a sample of a perfused article for testing.
  • Fig. 4 is a pictorial illustration of the zone inhibition test for antibacterial a c t i v i t y u s e d h e r e i n .
  • the infusion treatment used herein is carried out in specially made glass impregnation chambers similar in shape to the perfusion chamber 1 illustrated in Figs. 1 and 2.
  • These chambers typically can be long glass tubes sealed on the bottom and widened at the top to accommodate the swelling of the tubing and pump body or other device selected for infusion proceeding.
  • the chambers are also long and wide enough to accommodate the increased Length and width of the distal tubing upon swelling.
  • These special treatment chambers are designed specifically to accommodate the device to be infused and a sufficient quantity of solution is used to provide contact between the solution and all surfaces of the device.
  • the chambers are filled with the selected antimicrobial solution to within one inch of the upper lip of the top reservoir prior to priming the tube or other device being treated.
  • the clean, dry device to be impregnated is primed with one of the antimicrobial solutions described hereinafter, to fill the interior of the device, in this example a Denver Hydrocepha lus shunt (DHS) manufactured by Denver BiomatenaIs, Inc. of Evergreen, Colorado, making sure all air is expelled.
  • DHS Denver Hydrocepha lus shunt
  • This step is accomplished by placing the outflow end of the distal catheter into the treatment chamber and attaching a glass syringe filled with an antimicrobial solution onto the proximal (inflow) end of the shunt by depressing the syringe plunger until no more air comes out of the submerged distal end.
  • the pump body In the priming of a shunt, the pump body must be held with the valve end down to assure the expulsion of air bubbles from the pump body.
  • the proximal end is clamped approximately 0.5 inches from the end.
  • the syringe is then removed and the shunt is submerged in the solution up to the clamp.
  • the chamber is then filled with antimicrobial solution nearly to the top rim.
  • a small flexible wire is then inserted approximately 0.125 inches from the proximal end so as to pierce the tube crosswise, through diametrically opposite holes.
  • the wired end is then submerged in the antimicrobial solution and the clamp is removed. Care must be taken to submerge the tube completely at first.
  • the clamp is removed so that no air enters the tube.
  • the wire is. secured to the outside of the chamber so that it holds the tube below the surface of the liquid.
  • the silicone rubber shunts swell in the charging solution, they become buoyant and will rise sufficiently to project out of the charging chamber if they are not properly secured with the proximal end submerged in the treatment solution.
  • the processing time starts when the tube is fully submerged.
  • the chambers are covered, preferably with aluminum foil, to minimize the evaporation of the solvent from the charging solution during treatment.
  • the duration of the treatment is preferably about 30 minutes to one hour of contact with the solution, although the swelling itself may be substantially completed in approximately 10 minutes.
  • the charging chamber is checked visually during processing to be sure that the device has remained submerged.
  • the shunt is carefully pulled out of the chamber allowing the liquid inside the shunt to drain into the chamber.
  • the swelled silicone rubber is mechanically vulnerable at this stage and tears easily, especially at the wire in the proximal end. Therefore, it must be handled gently.
  • the treated shunt is immediately immersed in a denatured ethyl alcohol bath. This rinse reduces the spotting of the antimicrobial material on the outside of the shunt as it dries, and .does not noticeably reduce the level of the antimicrobial activity.
  • the shunt is then suspended in a vertical position, pump body up, and permitted to air dry at room temperature (21oC).
  • the shunt is then allowed to outgas in this position overnight.
  • An elevated temperature chamber may be employed to shorten the solvent evaporation and outgassing time as long as the temperature is not so high as to degrade the antimicrobial agents deposited in the device.
  • the shunts will usually have regained their initial size and shape within 10 minutes after they are removed from the charging chamber.
  • the treated shunt After outgassing, the treated shunt is briefly washed in running tap water and rinsed in deionized water, just as the shunt would normally be washed during a production run. It is again dried for a short period in a warm oven at a temperature not exceeding 200oF, as higher temperatures can cause decomposition of the antimicrobials. The treated shunt is then sterilized and/or tested taking care that it is stored in the dark at room temperature. Some antimicrobials are light sensitive and can lose activity upon prolonged exposure to light and excessive heat.
  • the antimicrobials used to impregnate the device are best prepared in solutions immediately before use. Because of the light sensitive nature of the agents and the volatile nature of the solvent, great care must be taken not to expose the solutions to direct sunlight or to store them in solution for any prolonged period prior to use. The solutions are discarded immediately after use. The antimicrobials are stored in a dry form according to the manufacturers recommendations. Immediately prior to use they are weighed on an analytical balance accurate to 0.1 mg. The optimum concentrations, determined by previous testing, are about 0.1% by weight of single antimicrobials and 0.1% each by weight in combinations. The antimicrobial solutions are brought to their desired volumes in analytical grade chloroform, the preferred solvent, and stirred until they are dissolved.
  • the preferred antimicrobials used in the process of the present invention are: (1) Rimactane (rifampin USP) (Ciba Pharmaceutical Company) which is a semisynthetic antibiotic derivation of rifamycin B (specifically, Rimactane is the hydrazone, 3-(4-methyl-1-piperazinyl-iminomethyl)-rifamycin SV.); and (2) Cleocin HCl (Upjohn Manufacturing Co.), which is clindamycin hydrochloride. These agents can be used singly or preferably in combination as a solute. Together they provide superior penetration, or deposition and persistent antimicrobial activity than they do when used singly in devices treated according to the present invention.
  • the perfusion chamber 1 is constructed in a shape to receive a medical device which has been infused with an antimicrobiaI agent or agents according to the present invention.
  • a Denver Hydrocephalus Shunt (DHS) with its valve and pump chamber 2 attached tubing 3 is shown.
  • This shunt is fabricated entirely of Dow Corning silicone rubber.
  • the perfusion chamber 1 can be shaped to accommodate any similar device equally well if the materials and methods described herein are employed.
  • the inflow tube 5 is attached to a glass stopper 6, after passing through a multi-channel peristaltic pump 7.
  • the glass stopper 6 is inserted in fluid-tight engagement with the open end or top of perfusion chamber 1.
  • a side arm 10 is also provided on perfusion chamber
  • an inflow reservoir 30 is provided which is adapted to lead the fluid composition selected for perfusion into each of the channels of the muIti-channeI peristaltic pump by means of manifold 31.
  • an air bleed chamber 16 is provided in the input tubing 5 between the glass stopper 6 and the multi-channel peristaltic pump 7.
  • the air bleed chamber 16 is provided with valve means 17 fastened to the top of the chamber 16 to operate as described hereinafter to assure that the liquid level in the chamber 16, as shown, is sufficiently high to assure covering the end of the inflow tubing 5.
  • the perfusion takes place as much as possible in a sterile environment, in a completely closed system, at zero head pressure, and at a rate of flow chosen to imitate the normal rate of Cerebrospinal fluid (CSF) production in the body.
  • CSF Cerebrospinal fluid
  • the system is designed to perfuse the inner and outer surfaces of the shunts or tubes simultaneously.
  • the shunts are sampled periodically and activity-tested in the layered zone inhibition test described hereinafter.
  • the perfusion apparatus consists of a multiplicity of specially designed glass perfusion chambers 1, inflow and outflow reservoirs 20 and 30, a multi-channel peristaltic pump 7 (Manostat Cassette Pump) and various tubing lengths which connect inflow reservoir to pump, to chambers and finally to the outflow reservoir, see Figs. 1 and 2.
  • peristaltic pump 7 Manostat Cassette Pump
  • the inflow and outflow reservoirs 20 and 30 are 20-liter Nalge bottles with a outflow spigot.
  • a glass tube plugged with loose cotton fiber at the top has been inserted through the cap of each bottle.
  • the lower end of the tube is positioned near the interior bottom of the inflow liquid reservoir. This assures a substantially constant low head pressure no matter what the liquid level may be in each reservoir, see Fig. 1.
  • the Manostat Cassette pump 7 operates by a peristaltic action.
  • Each channel can be adjusted to the desired flow rate by increasing or decreasing the flow resistance on the inflow side of the tube for that channel.
  • the size of the tubing which fits into each cassette has been chosen to deliver a constant and predetermined flow rate at a preselected speed of the pump in the system.
  • the liquid flows out of the pump and into an apparatus 16, which removes any air bubbles that have been generated by the peristaltic action before the fluid reaches the samples to be perfused.
  • the flow proceeds out of that apparatus 16 and flows directly into the top glass stopper 6 of the perfusion chamber.
  • the fluid then proceeds through the interior of the sample which is attached to the stopper and is submerged in the chamber.
  • the liquid moves out of the distal end of the shunt and flows back up the outside of the sample to exit the chamber at the side arm attachment 10 near the inflow glass stopper 6 see Fig. 2.
  • the liquid then flows into the outflow tubing 11 past a stopcock or valve 12, which enables the sampling of the eluate.
  • the liquid then flows into a manifold 15 which feeds into the outflow reservoir 20.
  • the inflow reservoir 30 is kept filled with sterile perfusion liquid and is never allowed to run dry.
  • the outflow reservoir is emptied and the eluate volume is measured every 24 hours to confirm that the overall selected rate of flow in the system has been maintained. Flow can also be monitored in each channel using a Gilmont flow meter incorporated in the system, not shown.
  • the following preparations are made before the perfusion tests are run: (1) The samples to be perfused have, as previously described, been impregnated, outgassed, washed and then sterilized by sufficient exposure to ethylene oxide gas. (2) The chambers have been acid-cleaned and dried. (3) The perfusion tubing has been washed and steam autoclaved at 250oF and 15 psi for 20 minutes. (4) The peristaltic pump in the testing apparatus has been routinely serviced and cleaned, before perfusion.
  • the perfusion chambers 1 are filled and the pumping apparatus, including the associated tubing is primed with sterile perfusion liquid
  • the ste ile shunts to be perfused are removed from their packaging, being handled at all times with sterile rubber gloves.
  • the shunts are primed with sterile perfusion liquid by forcing the liquid through them with a glass syringe. With all the air has been expelled from each shunt the proximal or inflow end is clamped off and is attached to inflow port on the glass stopper of the perfusion system.
  • the distal end is submerged in the perfusion chamber during this priming operation and, as the clamp is removed from the inflow end, the pump is started to initiate flow.
  • the glass stopper is seated in the top of the perfusion chambers and the stopcock 12 in the outflow tubing is turned to the open position. Air bubbles which may form in the pump chamber are carefully removed. The system is then allowed to run, making minor adjustments to maintain nearly constant flow, for the time of the experiment being performed. Daily maintenance of the test system, including the filling and emptying of the reservoirs, is also performed.
  • distal tubing segments are perfused for testing for activity against bacteria, samples of the material being perfused are taken at van us times during the perfusion run, as shown in Fig. 3.
  • the remaining tubing is re-attached to the inflow port of the glass stop.per and is resubmerged in the perfusion chamber 1.
  • the glass stopper 6 is secured in the top of the chamber and the outflow stopcock 12 is opened. Perfusion flow is then resumed and its rate is moni tored.
  • the samples to be tested are stored in a dark place at room temperature (21oC) until tested in the Layered zone inhibition test.
  • the culture is plated out on Columbia Blood Agar Base plates (Difco Laboratories, Detroit, Michigan) and allowed to grow for 24 hours in a 37oC incubator.
  • a drop of culture is removed from the stock aseptically with a sterile Pasteur pipette and is dropped onto a fresh Columbia Blood agar plate which has been dried for 30 minutes in a 37oC incubator. The drop is then spread on the plate with a sterile bacteriological loop to dilute and isolate the colonies.
  • the agar plates prepared for use in the layered zone inhibition test contain a prepoured bottom layer of agar which contains no bacteria.
  • the agar used is Diagnostic Sensitivity (DST) agar (oxoid USA, Columbia, Maryland).
  • DST Diagnostic Sensitivity
  • the agar is prepared according to the manufacturers direction (4g DST/100ml of deionized water) dissolved on a stirring hot plate and is placed in a heavy walled media bottle.
  • the prepared bottled agar is then steam autoclaved in a pressure sterilizer for 20 minutres at 250oF and 15 psi. After autoclaving, the bottle is cooled to 56oC in a heated circulating water bath and is held for 20 minutes.
  • the agar is then poured into clean sterile glass petri dishes, approximately 25 ml per dish. Six dishes are poured at one time (using a 6g DST/150 ml of deionized-H 2 O solution). After all six have been poured the surface of each agar plate is flame-sterilized by passing the bunsen burner flame rapidly over the surface. This flaming also removes any bubbles that may have formed on the surface during pouring. The plates are cooled and stored in a refrigerator until used.
  • samples to be tested have previously been treated and/or sterilized and/or perfused as described hereinbefore.
  • Samples in the agar plate test are always sampled and tested in triplicate.
  • the samples have been stored in a dry place, in the dark at room temperature until the zone inhibition test is set up.
  • the samples should be removed from storage just prior to testing. They are soaked (hydrated) in sterile deionized water for one hour at room temperature prior to being embedded in the plates.
  • the prepoured DST plates are removed from refrigeration and dried (as before) for approximately 20 minutes in a 37oC incubator.
  • the plates are labeled, including the sample data, the name of the antimicrobial used and the time and date of sampling.
  • the agar to be used in the overlayer is prepared as before, at a concentration of 7g DST/175ml of deionized water.
  • the agar is dissolved by stirring on a laboratory hot plate and poured into a heavy walled media bottle.
  • the bottle is then steam autoclaved in a pressure cooker sterilizer for 20 minutes at 250oF and 15 psi.
  • the pressure in the sterilizer has returned to zero the bottle is removed and placed in a 56oC circulating water bath for approximatey 20 minutes.
  • the previously prepared suspension of bacteria in peptone water is removed from the incubator.
  • the correct number of drops of suspension are then added aseptically to the agar bottle with a sterile Pasteur pipette to bring the final concentration of bacteria in the agar to 10 5 cfu/ml. Concentration of bacteria has been determined by Miles Misra counting and the Pasteur pipettes have been calibrated to determine volume per drop.
  • the bacterially seeded agar is mixed gently to distribute the bacteria evenly, being careful not to generate bubbles in the solution.
  • the solution is poured carefully onto the previously prepared dried agar plates. 175 ml of seeded solution is sufficient to overlayer 6 plates.
  • the samples to be tested are very quickly removed from the hydration solution with foreceps. They are shaken to remove surface water and blotted on clean filter paper. The samples are then rapidly embedded in the agar-bacterial overlayer oriented radially and placed about 120 from one another, i.e. three to a plate as shown in Fig. 4. Each sample tube is placed in the agar at a slight angle to the horizontal to facilitate the filling of the inside of the tube with liquid agar. The tubes must be placed firmly without any side to side skewing or other follow-on motion. Since diffusion of the antimicrobial agent begins immediately when the tube enters the agar, movement of the tube after it is first placed in the agar will result in nonuni form and indeterminate inhibition zones. The gar will set up within one minute after pouring onto the plate. When the plates have completely set, they are inverted and placed in an incubator for overnight culture (18-24 hours) at 37°C.
  • the developed plates are moved from the incubator and the zone sizes are measured as indicated in Fig. 4.
  • the plate is held with the lid off in front of a light source and the bacterial overlayer facing the technician.
  • the size of the zone is measured half way along the length of the tube to avoid measuring the zone producton that results from the cut ends of the tubes.
  • the diameter of the tube (2mm in the case of distal hydrocephalus shunt tubing) is subtracted from the observed value of the zone of inhibition and this number is recorded as the zone size.
  • the zone sizes of all three specimens on a plate are recorded. An average of those three values is taken to be the activity of the specimen against Staphlococcus aureus (in this example) for that point in time.
  • Table 1 The results of zone measurement after infusion, perfusion and testing, as described herein, are shown in Table 1.
  • antimicrobial agents tested included: (1) clindamycin HCl and (2) Rifampin, each at concentrations of .1% by weight.
  • Fig. 5 depicts graphically the average of the results summarized in Table 1. The graph demonstrates that the combination of .1% Rifampin plus .1% clindamycin CHI has retained nearly 75% of its activity after 28 days of continuous perfusion.

Abstract

Dispositif médical (3) imprégné d'une combinaison d'agents antimicrobiens (30) par l'action d'un agent gonflant et procédé d'imprégnation d'un dispositif médical (3) avec une combinaison d'agents antimicrobiens (30).
PCT/US1986/002668 1985-12-16 1986-12-11 Catheter antimicrobien et procede WO1987003495A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80923585A 1985-12-16 1985-12-16
US809,235 1985-12-16

Publications (1)

Publication Number Publication Date
WO1987003495A1 true WO1987003495A1 (fr) 1987-06-18

Family

ID=25200849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/002668 WO1987003495A1 (fr) 1985-12-16 1986-12-11 Catheter antimicrobien et procede

Country Status (6)

Country Link
EP (1) EP0252120A4 (fr)
JP (1) JPS63501932A (fr)
AU (1) AU597027B2 (fr)
CA (1) CA1308032C (fr)
IL (1) IL80984A (fr)
WO (1) WO1987003495A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393100A1 (fr) * 1987-11-23 1990-10-24 Colorado Biomedical Inc Procede et dispositif anti-microbiens.
EP0405284A2 (fr) * 1989-06-29 1991-01-02 Hercules Incorporated Cathéters imprégnés d'un produit pharmaceutique
DE4143239A1 (de) * 1991-12-31 1993-07-01 Joerg Dipl Chem Schierholz Pharmazeutische wirkstoffe enthaltende implantierbare vorrichtung aus einem polymeren material sowie verfahren zu deren herstellung
WO1994004202A1 (fr) * 1992-08-13 1994-03-03 Theodor Krall Objets bactericides et/ou fongicides en matieres plastiques a usage medical
DE19619327A1 (de) * 1996-05-14 1997-11-20 Dunzendorfer Udo Priv Doz Dr M Oberflächenbeschichteter Katheter
US6162487A (en) * 1995-11-08 2000-12-19 Baylor College Of Medicine Method of coating medical devices with a combination of antiseptics and antiseptic coating therefor
US7811317B2 (en) 1993-04-26 2010-10-12 Medtronic, Inc. Medical devices for delivering a therapeutic agent and method of preparation
US8075823B2 (en) 1999-07-30 2011-12-13 Guggenbichler J Peter Process for preparing antimicrobial plastic bodies having improved long-time performance
US8221392B2 (en) 2004-09-30 2012-07-17 Codman & Shurtleff, Inc. Fluid management flow implants of improved occlusion resistance
WO2017134049A1 (fr) 2016-02-01 2017-08-10 Schierholz Jörg Michael Produits médicaux implantables, leur procédé de préparation et leur utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4112151A (en) * 1976-01-09 1978-09-05 Monarch Marking Systems, Inc. Impregnating porous articles
US4224736A (en) * 1978-08-07 1980-09-30 Esb Inc. Process for sealing electrochemical cells
US4419322A (en) * 1982-09-27 1983-12-06 Akzona Incorporated Method for dilating plastics using volatile swelling agents
US4420514A (en) * 1981-04-17 1983-12-13 Mobil Oil Corporation Polymer film treatment with organic impregnant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3695921A (en) * 1970-09-09 1972-10-03 Nat Patent Dev Corp Method of coating a catheter
DE3272706D1 (en) * 1981-05-27 1986-09-25 Unitika Ltd Urethral catheter capable of preventing urinary tract infection and process for producing the same
US4605564A (en) * 1984-01-23 1986-08-12 Biological & Environmental Control Laboratories, Inc. Coating process for making antimicrobial medical implant device
US4612337A (en) * 1985-05-30 1986-09-16 The Trustees Of Columbia University In The City Of New York Method for preparing infection-resistant materials

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4112151A (en) * 1976-01-09 1978-09-05 Monarch Marking Systems, Inc. Impregnating porous articles
US4224736A (en) * 1978-08-07 1980-09-30 Esb Inc. Process for sealing electrochemical cells
US4420514A (en) * 1981-04-17 1983-12-13 Mobil Oil Corporation Polymer film treatment with organic impregnant
US4419322A (en) * 1982-09-27 1983-12-06 Akzona Incorporated Method for dilating plastics using volatile swelling agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0252120A4 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393100A4 (en) * 1987-11-23 1991-03-13 Colorado Biomedical Incorporated Antimicrobial device and method
EP0393100A1 (fr) * 1987-11-23 1990-10-24 Colorado Biomedical Inc Procede et dispositif anti-microbiens.
EP0405284A2 (fr) * 1989-06-29 1991-01-02 Hercules Incorporated Cathéters imprégnés d'un produit pharmaceutique
EP0405284A3 (en) * 1989-06-29 1991-03-27 Hercules Incorporated Pharmaceutically impregnated catheters
DE4143239A1 (de) * 1991-12-31 1993-07-01 Joerg Dipl Chem Schierholz Pharmazeutische wirkstoffe enthaltende implantierbare vorrichtung aus einem polymeren material sowie verfahren zu deren herstellung
EP0550875A1 (fr) * 1991-12-31 1993-07-14 Schierholz, Jörg, Dr.Dr. Dispositif implantable en matériau polymérisable contenant des agents pharmaceutiques et procédé pour sa production
EP0550875B1 (fr) * 1991-12-31 1998-04-29 Jörg Dr.Dr. Schierholz Dispositif implantable en matériau polymérisable contenant des agents pharmaceutiques et procédé pour sa production
WO1994004202A1 (fr) * 1992-08-13 1994-03-03 Theodor Krall Objets bactericides et/ou fongicides en matieres plastiques a usage medical
US5516480A (en) * 1992-08-13 1996-05-14 Peter Guggenbichler Bactericidal and/or fungicidal plastic parts for use in the medical field
US7811317B2 (en) 1993-04-26 2010-10-12 Medtronic, Inc. Medical devices for delivering a therapeutic agent and method of preparation
US6162487A (en) * 1995-11-08 2000-12-19 Baylor College Of Medicine Method of coating medical devices with a combination of antiseptics and antiseptic coating therefor
DE19619327A1 (de) * 1996-05-14 1997-11-20 Dunzendorfer Udo Priv Doz Dr M Oberflächenbeschichteter Katheter
US8075823B2 (en) 1999-07-30 2011-12-13 Guggenbichler J Peter Process for preparing antimicrobial plastic bodies having improved long-time performance
US8221392B2 (en) 2004-09-30 2012-07-17 Codman & Shurtleff, Inc. Fluid management flow implants of improved occlusion resistance
WO2017134049A1 (fr) 2016-02-01 2017-08-10 Schierholz Jörg Michael Produits médicaux implantables, leur procédé de préparation et leur utilisation
US11185616B2 (en) 2016-02-01 2021-11-30 Jörg Michael SCHIERHOLZ Implantable medical products, a process for the preparation thereof, and use thereof

Also Published As

Publication number Publication date
AU6839487A (en) 1987-06-30
JPS63501932A (ja) 1988-08-04
EP0252120A1 (fr) 1988-01-13
EP0252120A4 (en) 1990-09-26
AU597027B2 (en) 1990-05-24
IL80984A (en) 1993-06-10
CA1308032C (fr) 1992-09-29
IL80984A0 (en) 1987-03-31

Similar Documents

Publication Publication Date Title
US4917686A (en) Antimicrobial device and method
Bayston et al. Duration of protective activity of cerebrospinal fluid shunt catheters impregnated with antimicrobial agents to prevent bacterial catheter-related infection
AU2017201270B2 (en) Devices with anti-thrombogenic and anti-microbial treatment
Stillman et al. Etiology of catheter-associated sepsis: correlation with thrombogenicity
Archer et al. A controlled model of moist wound healing: comparison between semi-permeable film, antiseptics and sugar paste.
Taj et al. Study on biofilm-forming properties of clinical isolates of Staphylococcus aureus
Younger et al. Coagulase-negative staphylococci isolated from cerebrospinal fluid shunts: importance of slime production, species identification, and shunt removal to clinical outcome
AU597027B2 (en) Antimicrobial catheter and method
EP2272545B1 (fr) Article médical antimicrobien et son procédé de préparation
Hampl et al. In vitro and in vivo efficacy of a rifampin-loaded silicone catheter for the prevention of CSF shunt infections
EP1211935B1 (fr) Revetement anti-infectieux pour dispositifs d'acces percutane et vasculaire et procede de revetement
JP2007517557A (ja) 創傷被覆材
Bridgett et al. In vitro assessment of bacterial adhesion to Hydromer®-coated cerebrospinal fluid shunts
Brokke et al. Adherence of coagulase-negative staphylococci onto polyethylene catheters in vitro and in vivo: a study on the influence of various plasma proteins
Jansen et al. New aspects in the pathogenesis and prevention of polymer-associated foreign-body infections caused by coagulase-negative staphylococci
Bayston et al. Catheter colonisation: a laboratory model suitable for aetiological, therapeutic and preventive studies
Palm et al. Prevention of catheter-related infections by a new, catheter-restricted antibiotic filling technique
TR201814886T4 (tr) Transdermal venöz erişim kilitleme çözeltileri.
Jansen New concepts in the prevention of polymer-associated foreign body infections
Lew Physiopathology of foreign body infections
CN117160829A (zh) 一种植入式生物传感器或留置针上的两性离子聚合物涂覆方法
CN115260558A (zh) 一种实现抗生物膜粘附与杀菌功能的表面处理方法
JP2000333934A (ja) 抗菌性を有する採血用ホルダー

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987900517

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987900517

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1987900517

Country of ref document: EP